PetMedix™ has announced the completion of an oversubscribed $37M (£27M) Series B financing round that will be used to advance its innovative pipeline through clinical development. The investment brings two new investors into PetMedix: global technology company Tencent and Japanese corporation Kyoritsu Holdings alongside strong continued support from U.S.-based investor Digitalis Ventures, and British funds Parkwalk Advisors and Cambridge Innovation Capital.